Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
127.74
+0.62 (0.49%)
At close: Nov 12, 2024, 4:00 PM
128.10
+0.36 (0.28%)
Pre-market: Nov 13, 2024, 5:43 AM EST

Company Description

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally.

The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders.

The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders.

The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc
Jazz Pharmaceuticals logo
Country Ireland
Founded 2003
IPO Date Jun 1, 2007
Industry Biotechnology
Sector Healthcare
Employees 2,800
CEO Bruce Cozadd

Contact Details

Address:
Waterloo Exchange, Fifth Floor
Dublin, D04 E5W7
Ireland
Phone 353 1 634 7800
Website jazzpharma.com

Stock Details

Ticker Symbol JAZZ
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001232524
CUSIP Number G50871105
ISIN Number IE00B4Q5ZN47
Employer ID 98-1032470
SIC Code 2834

Key Executives

Name Position
Bruce C. Cozadd Co-Founder, Chairman and Chief Executive Officer
Renee D. Gala President and Chief Operating Officer
Patricia Carr Senior Vice President and Chief Accounting Officer
Neena M. Patil J.D. Executive Vice President and Chief Legal Officer
Dr. Robert Iannone M.D. Executive Vice President, Chief Medical Officer and Global Head of Research and Development
Philip L. Johnson Executive Vice President and Chief Financial Officer
Andrea N. Flynn Ph.D. Vice President and Head of Investor Relations
Heidi Manna Executive Vice President and Chief People Officer
Dr. Jed Black M.D. Senior Vice President of Sleep and CNS Medicine
Samantha Pearce Executive Vice President and Chief Commercial OfficerChief Commercial Officer

Latest SEC Filings

Date Type Title
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 144 Filing
Nov 7, 2024 10-Q Quarterly Report
Nov 6, 2024 8-K Current Report
Nov 1, 2024 144 Filing
Oct 21, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 16, 2024 8-K Current Report
Sep 6, 2024 8-K Current Report
Sep 5, 2024 144 Filing
Aug 28, 2024 8-K Current Report